Short VUZI. Fraud.

March 16, 2018
  • This report is the opinion of the author. The author is short VUZI.
  • Vuzix recently used an undisclosed stock promotion involving dozens of mainstream media outlets to artificially inflate the share price and volume, and then raise $30 million
  • Photos of leaked documents from IRTH Communications show IRTH bragging to potential clients that it was responsible for more than 30 articles from mainstream media outlets which all simultaneously erupted in connection with Margolis’ “Alexa ruse”. These specific IRTH sponsored articles were conspicuous in that they offered effusive praise for Vuzix but appeared as standard news on dozens of mainstream sites
  • The information contained in the articles and product reviews was flat out wrong, but was then repeatedly re-broadcast by Vuzix (esp. Margolis) in order to inflate the stock. Margolis made heavy use of social media, adding the $VUZI ticker next to the sponsored articles
  • Vuzix’s “Blade” is little more than a low tech mock-up which serves as a prop for journalists to conduct sham reviews. When these journalists “reviewed” the product at CES, neither the Alexa feature nor the browser were functioning – not for any of the journalists. Yet these same journalists then widely touted the device in their mainstream bylines, overwhelmingly on the basis of the Alexa features that actually don’t exist !
  • Matt Margolis conceals his past employment by multiple fraudsters who had also been behind undisclosed promotions on Vuzix for years. Margolis’ former employer Mark Gomes was shut down under SEC fraud proceedings in September just after running his latest promotion on Vuzix
  • With a separate promoter, Margolis was actively promoting Cemtrex and other IRTH clients without disclosing that he was being paid via IRTH Communications. Cemtrex subsequently collapsed.
  • Vuzix’s recent “Alexa ruse” was actually a recycled ploy that Margolis had used on Vuzix in 2016,while he was still employed by outside promoters. Just like with the “GoPro ruse” in 2016, adding Alexa functionality costs nothing and can be done in just one hour by downloading a simple developer kit. Margolis then uses this non-event as a pretense to run a stock promotion
  • Over the past 11 months, we have seen a very visible acceleration in SEC enforcement against this exact type of fraud. The recent undisclosed IRTH promotions were now too blatant and were then used for an immediate $30 million capital raise at $9.95. Investors in that offering ended up seeing nearly immediate losses after the pump campaign stopped.

 

Summary

  • In Oct 2017, shares of ABEO hit a new high of $19.55 following the release of seemingly positive data in its clinical trial for MPS-III.
  • ABEO quickly used that strength to raise money in an equity offering at $16 in October.
  • But when additional data was released last week, ABEO quickly began to plunge every day.
  • “Smart money” investors now realized that Cohort 1 data had been badly manipulated to show optimal results.
  • Out of a three person Cohort, one patient was given an arbitrary “floor score” for a cognitive test – precluding any real chance of further declines in cognitive ability. Another patient was removed from the trial altogether.  
  • This information was not made clear in October at the time of the equity offering
  • In addition, Cohort 2 data was visibly mixed, with the strongest results coming from a disputed test method and with very negative indications coming from the industry standard test
  • The leading industry journal specifically recommends two different tests than the one being used by ABEO. The non recommended test is the one which analysts continue to cite as indication of strong results.
  • The investors who have figured this out have been selling heavily every day since that data was released on Feb 8th.
  • Yet sell side analysts continue to put positive spin on the results by focusing on a single “outlier” to explain negative results.

Summary

  • As much as 30-40% of Euronet’s profits and EBITDA are generated solely by DCC revenues with ultra high margins. The sell side has largely missed this entirely.
  • During 2017, scathing public criticism erupted from a wide array of journalists, travel advisers and celebrity TV hosts, directly alleging Euronet “fraud”, “rips offs” and “scams” with DCC. Evidence posted in photos, screenshots and videos.
  • Multiple independent investigations then concluded specifically that “DCC should be banned”
  • Following the public scrutiny, a wide range of Euronet insiders began aggressively dumping their shares (and just ahead of a key vote in November 2017 by the EU Parliament)
  • Since then, EU legislation covering DCC has passed multiple key milestones.
  • Final regulations are set to be passed by June 2018
  • Euronet trades on a steep premium to peers because of perceived growth prospects. Any reassessment will see disproportionate downside to the share price

Summary: In over 20 years SSTI has never generated profits or meaningful cash. Recent IPO simply allows VCs to finally exit positions. Dec 4th lockup expiration on 8 million shares Reams of independent data and test use confirm that SSTI ‘s technology simply doesn’t work. Period. Customers repeatedly describe overwhelming failure rate. Aggressive tactics by…

Read More

Summary New data points: Fraud penalties expected to reach $100 million or more. Other insurers required to cease doing business with HIIQ as part of their fraud settlements. June 2017: HIIQ rejected for key insurance license in home state of Florida as regulator uncovers undisclosed legal actions against HIIQ insiders. HIIQ privately warns of disastrous…

Read More

Summary ARA’s JV partners are suddenly exercising their put options nearly as fast as they vest, requiring ARA to buy out their equity stakes. The reasons are becoming clear. Post Q1 news: insurers now rejecting charitable assist on BOTH ACA AND non-ACA plans. Fraud lawsuit against ARA spurred federal investigations into “charities”, now from three…

Read More

Summary In over 100 articles I have seldom used the word fraud to describe concerns. I reserve that word for the very worst situations where I have the highest confidence. Within a few months after I expressed my fraud concerns on Osiris, we saw a CEO resignation, sweeping restatement of inaccurate financials and a criminal…

Read More

Summary On Tuesday, Cemtrex fell 13% on huge volume. On the preceding trading day, Cemtrex’s banker Source Capital quietly had its SEC and FINRA registrations terminated following multiple violations. Over $1 million has been paid to notorious stock promoters sending CETX soaring from below $2. Heavy undisclosed selling by CETX insiders during paid promotion. DOCUMENTS:…

Read More

Summary Shares of YRD have been shunned by traditional China smart money. Outside ownership is dominated by a few US “quant funds” who perform little fundamental research. Existing concerns have weighed on the stock including fraud, an explosion of guaranteed subprime credit exposure and new illegal activities in China. To entice lenders, YRD guarantees deep…

Read More

Summary Bone Growth Stimulators (“BGS”) comprise the largest segment of revenue and more than half of profits, while also driving growth at Orthofix. Other segments are lower margin, commodity businesses and/or showing declines and pricing pressure. BGS is absolutely the only reason to own Orthofix. October 2016: FDA is actively moving to “down classify” BGS…

Read More

Summary Nymox withheld the data that Phase 3 trials of its only drug had failed for 6-12 months after management knew of the failure. During this time, Nymox issued bullish press releases while management continued to aggressively dump stock without timely SEC disclosure. Offshore anonymous Panamanian finance deals; auditor, legal counsel, bankers ALL closely tied…

Read More

Bristow is down by 80% since mid 2015 as bankruptcy fears continue to slowly play out. The moderate recovery in oil prices has been unable to help Bristow recover. Bristow has just suffered a massive impact due to excess unhedged currency exposure to the British Pound (quite bad) and the imploding Nigerian Naira (even worse)….

Read More

Summary OraSure dipped just slightly from its 2016 highs on a recent report from Raymond James downgrading OraSure to a “Market Perform”. The report completely dismissed significant near-term problems for OraSure. Another BTIG analyst has been quick to defend the stock. As shown below, OraSure is virtually guaranteed to lose a very lucrative deal with…

Read More

Summary Since I last highlighted fraud concerns at Osiris, the stock has fallen by 40%. I expect an additional 50% drop based on new catalysts. The CEO has since resigned unexpectedly. Osiris is unable to file its 10K and has now received a NASDAQ deficiency notice. Last week, Osiris’ head of sales has just been…

Read More

Summary In 2014, CEC pulled an accounting gimmick in order to remain “financially responsible” in the eyes of the Department of Education (“ED”). Calculations indicate that CEC’s failure to sell Le Cordon Bleu will result in its Composite Score plunging to below 0.7 – deep into the category of “not financially responsible”. CEC is already…

Read More

Summary Revance has soared 50% to all-time highs based on preliminary data from a Phase 2 study, which appeared to indicate that its RT002 was superior to Allergan’s Botox. Revance has deliberately shown misleading data and withheld the real information, which would actually be required for FDA approval. The CMO quit one day after the…

Read More

Summary Tokai’s attempt at a Phase 3 trial is based on data from just 6 patients out of 87 in Phase 2, based on after-the-fact cherry picking of data. Tokai dramatically changed its trial design between Phase 2 and Phase 3, and the FDA has already warned Tokai about problems with its trial design. Insider…

Read More

Summary IPO’d at $18 with 100% of shares coming from insiders cashing out (company received no proceeds). Stock fell immediately and has now fallen by 33%. Company is saddled with debt and has no cash to conduct acquisitions. IPO was rushed out due to rapidly falling growth rates and margins. At least 30-40% further downside….

Read More

Summary Omeros recently spiked on release of new Phase II drug data for OMS-721. The stock quickly gave up almost all of these gains once the details of this trial were better understood. Omeros had previously been hitting a new 52-week low of $11.93 due to the failed launch of its only commercial product, Omidria….

Read More